Excess weight is a major driver of obstructive sleep apnea, and modest weight change shifts its severity. Zepbound (tirzepatide) became the first FDA-approved medication for moderate to severe sleep apnea in adults with obesity in December 2024.
Body weight is one of the strongest influences on obstructive sleep apnea, and even moderate changes in weight shift how severe it is. In December 2024, the FDA approved Zepbound (tirzepatide) as the first medication for moderate to severe obstructive sleep apnea in adults with obesity, based on trials in which breathing interruptions dropped substantially over a year. Breathing devices such as CPAP remain the standard treatment, and a GLP-1 medication is something to add or consider with a licensed provider, not a reason to set your device aside.
The National Heart, Lung, and Blood Institute (NHLBI) describes sleep apnea as a common condition in which breathing stops and restarts many times during sleep. In the obstructive type, the airway repeatedly closes. (Central sleep apnea is different: the brain does not send the signals needed to breathe.)
Signs that something may be wrong include:
NHLBI lists obesity, large tonsils and changes in hormone levels as factors that can narrow the airway and raise risk. Left untreated, sleep apnea increases the risk of stroke, heart attack and other serious problems. To check for it, your provider may have you do a sleep study.
Sleep studies count apneas (pauses in breathing) and hypopneas (shallow breathing) per hour of sleep. This is the apnea-hypopnea index, or AHI. The JAMA study described below defined moderate to severe sleep apnea as an AHI of 15 or more events per hour.
A study published in JAMA in 2000 followed 690 randomly selected adults in Wisconsin, testing each person's sleep twice, 4 years apart. Compared with people whose weight stayed stable:
The authors concluded that programs producing "even modest weight control" are likely to help manage sleep apnea and reduce new cases. That relationship is what made weight-reducing medications a logical candidate for treatment.
SURMOUNT-OSA, published in the New England Journal of Medicine in 2024, was actually two 52-week trials in adults with moderate to severe obstructive sleep apnea and obesity:
Participants started with severe disease: average AHI was 51.5 events per hour in trial 1 and 49.5 in trial 2, with an average BMI around 39. Results at 52 weeks:
| Tirzepatide | Placebo | Difference | |
|---|---|---|---|
| Trial 1 (no PAP), change in AHI | -25.3 events per hour | -5.3 events per hour | -20.0 |
| Trial 2 (on PAP), change in AHI | -29.3 events per hour | -5.5 events per hour | -23.8 |
Tirzepatide also improved measures of oxygen drops during sleep (hypoxic burden), patient-reported sleep impairment, an inflammation marker (hsCRP) and systolic blood pressure. The most common side effects were gastrointestinal and mostly mild to moderate. These are average results; individual responses vary.
On December 20, 2024, the FDA approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, used with a reduced-calorie diet and increased physical activity. The agency called it "the first drug treatment option for certain patients with obstructive sleep apnea." The FDA noted that more participants on Zepbound reached remission or mild sleep apnea with resolution of symptoms than on placebo, and that the improvement "is likely related to body weight reduction."
Semaglutide also produces substantial weight loss, so given the weight and sleep apnea relationship above, it is natural to wonder whether it helps. However, the Wegovy label does not include sleep apnea as an approved use. Using semaglutide specifically to treat sleep apnea would be off-label, and the dedicated outcome data described in this article come from tirzepatide.
Compounded semaglutide and compounded tirzepatide are not FDA-approved for any condition, including sleep apnea, and were not the products studied in SURMOUNT-OSA.
The American Academy of Sleep Medicine's 2019 guideline strongly recommends PAP therapy for adults with obstructive sleep apnea who have excessive sleepiness, and conditionally recommends it for those with impaired sleep-related quality of life or high blood pressure. It also strongly recommends education when starting PAP, and suggests troubleshooting support and remote monitoring early on to help people stick with it.
The SURMOUNT-OSA design reflects this. People in trial 2 kept using PAP throughout, and those on tirzepatide still saw larger AHI reductions than those on placebo. In other words, the medication was studied as an addition to standard care, not a replacement for it. Your sleep clinician decides whether and when your PAP plan should change.
If you use CPAP and start a weight management medication, keep using your device unless your sleep clinician tells you otherwise. Dosing of any medication is set by your prescriber.
Weight loss can reduce severity, and some people improve enough to reach mild disease or remission. In the JAMA cohort, a 10 percent weight loss predicted about a 26 percent drop in AHI on average. Whether it has improved enough for a given person is something to assess with your sleep clinician, not assume.
Yes. Since December 2024, Zepbound has been FDA-approved to treat moderate to severe obstructive sleep apnea in adults with obesity, alongside diet and physical activity. It is not approved for central sleep apnea or for people without obesity.
Not on your own. Sleep medicine guidelines strongly recommend PAP for people with sleep apnea and excessive sleepiness, and the tirzepatide trial included people who kept using PAP. Talk to your sleep clinician about how your plan should be reviewed after significant weight change.
Semaglutide is not FDA-approved for sleep apnea, so using it for that purpose would be off-label. Weight loss in general is linked to lower sleep apnea severity, but the dedicated trial evidence for a GLP-1 medication in sleep apnea comes from tirzepatide.
If you snore heavily, wake up gasping or feel exhausted during the day, ask a licensed provider about a sleep evaluation. If you already have a sleep apnea diagnosis and carry excess weight, bring your most recent sleep study results to a conversation about weight management options. You may also find our article on why obesity is treated as a chronic disease useful context. This article is educational and does not determine eligibility for any treatment.
Written by the NewDay Wellness editorial team from the sources above and checked against them before publication, and medically reviewed by Dr. Sean Arora and Dr. Shannon Arora of Arora Health & Aesthetics; see our editorial standards. This article is educational and does not diagnose conditions, establish eligibility for any medication, or replace care from a licensed provider. Compounded medications are not FDA-approved.
GLP-1 results vary widely. In trials, most people reached at least 5 percent weight loss while a minority did not. Medication and dose, type 2 diabetes, staying on treatment and early response all help explain the spread.
Read article
You can travel, celebrate and eat out on a GLP-1 medication with some planning: keep medication in your carry-on and follow your pharmacy's storage instructions, order smaller portions, keep fluids up, and ask your prescriber how to handle timing changes.
Read article
An underactive thyroid can add modest weight and fatigue, so a TSH test is a sensible check if you have symptoms. Separately, GLP-1 labels warn against use with a personal or family history of medullary thyroid cancer or MEN 2, so share your full thyroid history.
Read article